Company:  AXOVANT GENE THERAPIES LT ... (AXGT)
Form Type:  8-K
Filing Date:  11/8/2019 
CIK:  0001636050 
Address:  11-12 ST. JAMES'S SQUARE
SUITE 1, 3RD FLOOR
 
City, State, Zip:  LONDON,  SW1Y 4LB 
Telephone:  44 203 318 9708 
Fiscal Year:  03/31 
Last Trade
Last Trade: 
$5.53  
Change: 
-0.07 (-1.25%)  
Trade Time: 
Dec 13  
Market Cap: 
$126.04M
Trade AXGT now with 

© 2019  
Description of Business
We are a clinical-stage company focused on developing innovative gene therapies for neurological diseases. We are developing a pipeline of innovative product candidates for the treatment of these debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease). We are dedicated to realizing the potential of gene therapies to offer transformative patient outcomes in areas of high unmet medical need. We have assembled a portfolio of gene therapies in partnership with leading scientific institutions and have built a team with extensive experience in the gene therapy space. We will continue to build integrated internal development capabilities from product development through commercialization, with a focus on accelerating the pace of product development in the clinic.
Register and access this filing in:     
  FORM 8-K
    SECTION 5 CORPORATE GOVERNANCE
      Item 5.02 Departure of Directors or Certain Officers; ...
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    EXHIBIT INDEX
    SIGNATURE
  EXHIBIT 10.1
  EXHIBIT 10.2
  EXHIBIT 10.3